โšกYour ready-to-use recruitment solution: IRB-compliant, SEO-optimized website that automatically routes qualified patient leads to your clinical study (14-day free trial, then $44/mo)

Gene Therapy for ACM Due to a PKP2 Pathogenic Variant

Sponsored by Lexeo Therapeutics

Quick Self-Assessment

See if you qualify and express your interest

Preparing your pre-screening questions...

Current Status

Active, Not Recruiting

Auto-verified from ClinicalTrials.gov

Verified Nov 12, 2025

Phase

Clinical Trial

Sponsor

Lexeo Therapeutics

Enrollment Target

10

Start Date

Feb 2024

๐Ÿ“Š
1 of 10 participants interested
10% interest

Express Your Interest Today

Interested in learning more? Complete the form below.

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Advance Medical Science

    Contribute to groundbreaking research

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel (varies by study)

  • Help Others

    Benefit future patients

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3In-person assessment if eligible
  4. 4Begin participation

About This Study

This is a Phase 1/2, first-in-human, open-label, intravenous, dose-escalating, multicenter trial that is designed to assess the safety and tolerability of LX2020 in adult patients with PKP2-ACM

Who Can Participate

Inclusion Criteria

Adults with a clinical diagnosis of ACM meeting the 2010 revised Task Force Criteria (TFC)
Genetic testing documenting a pathogenic or likely pathogenic variant in PKP2
Frequent premature ventricular complexes (PVCs)
Implantable cardioverter-defibrillator (ICD) implantation โ‰ฅ 12 weeks prior to the pre-screening MRI
Left ventricular ejection fraction โ‰ฅ 40% Selected

Exclusion Criteria

Evidence of variant(s) in addition to PKP2 that meets the standard criteria to be considered pathogenic or likely pathogenic for ACM
Other cardiac abnormalities as specified in the protocol
New York Heart Association Functional Class IV at the time of consent
History of prior gene transfer therapy

โ“ Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility during the screening process.

Study Details

๐Ÿ“‹

Study Type

INTERVENTIONAL

๐Ÿ‘ฅ

Target Enrollment

10 participants

๐ŸŽ‚

Age Range

18 Years - 65 Years

โšง

Gender

ALL

๐Ÿข

Sponsor

Lexeo Therapeutics

Study Locations

Choose your preferred location or select flexible during enrollment

Unknown

Stanford

California

Location available
View Stanford location page
Unknown

Baltimore

Maryland

Location available
View Baltimore location page
Unknown

Ann Arbor

Michigan

Location available
View Ann Arbor location page
Unknown

Rochester

New York

Location available
View Rochester location page
Unknown

Charleston

South Carolina

Location available
View Charleston location page

Frequently Asked Questions

Q:What is a clinical trial?

A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.

Q:Will I be compensated?

Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.

Q:Will I receive a placebo instead of treatment?

When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.

Q:Can I leave a trial if I change my mind?

Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.

Q:How long does a clinical trial last?

Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.

Still have questions? Our study coordinators are here to help.

Ready to Make a Difference?

Express your interest in this groundbreaking clinical trial

๐Ÿ”’ Secure ยท ๐Ÿฅ Expert Care

Find More Cardiomyopathy Trials by City

Browse all cardiomyopathy clinical trials in these cities โ€” not just this study.

Looking for Arrhythmogenic Cardiomyopathy Treatment in Stanford?

Join others in California exploring innovative treatment options through clinical research

Arrhythmogenic Cardiomyopathy Treatment Options in Stanford, California

If you're searching for Arrhythmogenic Cardiomyopathy treatment in Stanford, participating in a clinical research study may provide access to innovative approaches under expert medical supervision. This study is actively recruiting participants in Stanford, Baltimore, Ann Arbor and surrounding areas.

Clinical trials offer participants the opportunity to receive cutting-edge treatments while contributing to medical research that may help future patients with Arrhythmogenic Cardiomyopathy. All study-related care is provided at no cost to participants.

Local Sites
3 locations in California
Now Enrolling
Up to 10 participants
Quick Start
Screening available now

Why Consider a Clinical Trial for Arrhythmogenic Cardiomyopathy?

Potential Benefits

  • โœ“Access to new treatment approaches before public availability
  • โœ“Close monitoring by experienced medical professionals
  • โœ“Study-related care provided at no cost
  • โœ“Contribute to medical research for Arrhythmogenic Cardiomyopathy

What to Expect

  • โ†’Initial screening to determine eligibility
  • โ†’Regular check-ups and monitoring visits
  • โ†’Possible compensation for time and travel
  • โ†’You can withdraw at any time

Frequently Asked Questions About This Arrhythmogenic Cardiomyopathy Study

Important Clinical Trial Information

This information is provided for educational purposes and does not constitute medical advice. Clinical trial participation involves potential risks and benefits. Eligibility requirements apply and will be assessed during the screening process.

Study identifier: NCT06109181. For complete study details, visit ClinicalTrials.gov. Always consult with your healthcare provider before making decisions about your medical care or participating in clinical research.